Managing 'terrible tetrad' requires proper mix of recognition, patience
While complications are inevitable for busy surgeons, focusing attentionremoves a lot of risk
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.